ReviewJournal of clinical medicine2025
Hyaluronidase Use in Aesthetic Medicine: Formulations, Safety, and Clinical Practice.
Review in Journal of clinical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Atypical Hyaluronic Acid-Induced Vascular Occlusion Masked by a Hematoma: Ultrasound-Guided Diagnosis and Management.Cureus · 2026Article
- Hyaluronidase-enhanced delivery in gene therapy and regenerative medicine for improved vector, cell, and cargo access.Frontiers in drug delivery · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rising number of Hyaluronic acid (HA) filler applications has led to an increase in the incidence of complications, which can range from undesired aesthetic outcomes to severe vascular occlusion events. Hyaluronidase (Hyal) hydrolyzes HA molecules and represents the preferred treatment for managing complications associated with HA fillers. Although Hyal formulations are safe and effective, Hyal use for treating complications of aesthetic procedures remains off-label in many countries due to the lack of standardized protocols and varying recommendations on dosing strategies. Here, we review the use of Hyal in aesthetic medicine, focusing on the available formulations, including galenic preparations, and the associated risks. We provide an update on the current clinical practice for Hyal administration by reviewing cases reported in the literature from 2020 to 2025. We summarize the current dosage strategies and administration techniques for treating different complications, with details on newly developed protocols, the implementation of imaging guidance, and adjunctive treatments. Despite the great variability in dosage and protocols, Hyal administration is a safe and effective treatment to manage complications and undesired aesthetic outcomes caused by HA fillers. Future efforts should focus on developing standardized protocols to facilitate the decision-making process, reduce response time, and ensure successful outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.